CompletedPhase 1NCT00313599
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
Studying Extragonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Mark M. Moasser, MDUniversity of California, San Francisco
- Intervention
- lapatinib(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2013
Study locations (1)
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00313599 on ClinicalTrials.govOther trials for Extragonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06418789High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell TumorsN.N. Petrov National Medical Research Center of Oncology
- RECRUITINGPHASE3NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02375204Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell TumorsAlliance for Clinical Trials in Oncology